Biora Therapeutics reports positive interim results for BT-600 clinical trial using NaviCap™ to deliver tofacitinib to the colon for ulcerative colitis treatment.
Biora Therapeutics reports positive interim results for its BT-600 clinical trial, a drug-device combination using NaviCap™ to orally deliver tofacitinib to the colon for potential ulcerative colitis treatment. The single-ascending dose (SAD) trial met pharmacokinetic endpoints, with devices performing well and no serious adverse events. The multiple-ascending dose (MAD) portion is ongoing, with final results expected in late Q2 2024.
April 04, 2024
3 Articles